Weidong Nie
Overview
Explore the profile of Weidong Nie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lu G, Li X, Xu W, Zhang F, Chen X, Wu H, et al.
Biomed Mater
. 2025 Mar;
PMID: 40081015
Nanozymes based on metals have been regarded as a promising candidate in the metabolic reprogramming of low-survival, refractory glioblastoma multiforme (GBM). However, due to size limitations, nanozymes struggle to balance...
2.
Shen S, Xue G, Zeng Z, Peng L, Nie W, Zeng X
Naunyn Schmiedebergs Arch Pharmacol
. 2025 Mar;
PMID: 40056202
Toosendanin (TSN) can inhibit the malignant process of many cancers, and has the potential to be developed as an anti-tumor drug. However, the role and mechanism of TSN in prostate...
3.
Cheng R, Li S, Ma X, Zhuang W, Lei Y, He J, et al.
Sci Adv
. 2025 Feb;
11(8):eadr1299.
PMID: 39970209
Tertiary lymphoid structures (TLSs) usually lead to significantly improved clinical benefits in immunotherapy but are rarely observed within native tumors. The current approaches are difficult in effectively inducing TLS formation,...
4.
Ma X, Mao M, Liu Z, Liang C, He J, Qu Y, et al.
J Am Chem Soc
. 2024 Nov;
146(46):31873-31884.
PMID: 39504515
Simultaneous detection of different biomarkers related to the spatiotemporally dynamic immune events is of particular importance for the accurate evaluation of antitumor immune effects. Here, we have developed an AND-gate...
5.
He J, Liang C, Yu X, Ma X, Qu Y, Zhuang W, et al.
Anal Chem
. 2024 Aug;
PMID: 39140208
Monitoring the effector function of cytotoxic T lymphocytes (CTLs) remains a great challenge. Here, we develop a chemistry-enabled enzymatic labeling approach to evaluate the tumor-specific immune response of CTLs by...
6.
Li Z, Xie H, Nie W
ChemMedChem
. 2024 Feb;
19(10):e202300647.
PMID: 38356248
Nanodelivery systems (NDSs) provide promising prospects for decreasing drug doses, reducing side effects, and improving therapeutic effects. However, the bioapplications of NDSs are still compromised by their fast clearance, indiscriminate...
7.
Nie W, Jiang A, Ou X, Zhou J, Li Z, Liang C, et al.
Biomaterials
. 2023 Dec;
304:122396.
PMID: 38043464
As natural adjuvants, the bacterial outer membrane vesicles (OMV) hold great potential in cancer vaccines. However, the inherent immunotoxicity of OMV and the rarity of tumor-specific antigens seriously hamper the...
8.
Liang C, He J, Zhao X, Hong J, Ma X, Mao M, et al.
Angew Chem Int Ed Engl
. 2023 Aug;
62(43):e202304838.
PMID: 37650228
Monitoring the highly dynamic and complex immune response remains a great challenge owing to the lack of reliable and specific approaches. Here, we develop a strategy to monitor the cascade...
9.
Zuo L, Nie W, Yu S, Zhuang W, Liang C, Li S, et al.
Nano Lett
. 2023 Mar;
23(7):3005-3013.
PMID: 36988626
Mitochondria are crucial for both sonodynamic therapy and antitumor immunity. However, how to accurately damage mitochondria and meanwhile prevent the mitophagy and immune checkpoint inhibition is still a great challenge....
10.
Zhuang W, Wang Y, Nie W, Lei Y, Liang C, He J, et al.
Nat Commun
. 2023 Mar;
14(1):1675.
PMID: 36966130
Efferocytosis inhibition is emerging as an attractive strategy for antitumor immune therapy because of the subsequent leak of abundant immunogenic contents. However, the practical efficacy is seriously impeded by the...